2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines

Abstract

Aim: The "2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy" provides recommendations to guide clinicians in the management of patients with hypertrophic cardiomyopathy.

Methods: A comprehensive literature search was conducted from September 14, 2022, to November 22, 2022, encompassing studies, reviews, and other evidence on human subjects that were published in English from PubMed, EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to this guideline. Additional relevant studies, published through May 23, 2023, during the guideline writing process, were also considered by the writing committee and added to the evidence tables, where appropriate.

Structure: Hypertrophic cardiomyopathy remains a common genetic heart disease reported in populations globally. Recommendations from the "2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy" have been updated with new evidence to guide clinicians.

Keywords: AHA Scientific Statements; athlete; atrial fibrillation; cardiac myosin inhibitors; cardiovascular magnetic resonance imaging; diastolic dysfunction; echocardiography; exercise, exercise stress testing; family screening; genetics; hypertrophic cardiomyopathy; implantable cardioverter defibrillator; left ventricular outflow tract obstruction; occupation; physical activity; pregnancy; rhythm monitoring; risk stratification; sarcomeric genes; septal alcohol ablation; septal reduction therapy; shared decision-making; sports, sudden cardiac death; surgical myectomy; systolic dysfunction; ventricular arrhythmias.